Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164). The gene discussed is CD19; the disease is cancer.